<DOC>
	<DOCNO>NCT02262299</DOCNO>
	<brief_summary>A European multi-centre , randomise , double-blind placebo-controlled trial Pirfenidone bronchiolitis-obliterans-syndrome grade 1-2 lung transplant recipient . Randomized double blind , placebo control study . Eligible patient randomize 1:1 ratio receive either Pirfenidone 2403 mg/d match placebo treatment 6 month . Primary objective To evaluate effect Pirfenidone change FEV1 liters 6 month lung transplant recipient bronchiolitis obliterans syndrome .</brief_summary>
	<brief_title>European Trial Pirfenidone BOS , A European Multi-center Study</brief_title>
	<detailed_description>Title study : A European multi-centre , randomise , double-blind placebo-controlled trial Pirfenidone bronchiolitis-obliterans-syndrome grade 1-2 lung transplant recipient Study design : Randomized double blind , placebo control study . Eligible patient randomize 1:1 ratio receive either Pirfenidone 2403 mg/d match placebo treatment 6 month . Study objectives Primary objective : Change FEV1 liters 6 month lung transplant recipient bronchiolitis obliterans syndrome . Secondary objective : - Categorical percentage change FEV1 - Change Forced Vital Capacity ( FVC ) - Change Total Lung Capacity ( TLC ) - Change FEV1/FVC ratio - Number patient treatment failure - Change BOS grade - Change percent predict diffusion capacity ( DLCO ) - Change functional level assess 6MWT - Hospital admission reason - Death re-transplantation rate - Change QoL assess EQ5D Methodology The study conduct select Lung Transplant expert center across Europe . Trial duration Enrolment duration : 15 month Treatment duration : 6 month Number patient Number sit Number country ~80 patient ( ~40 per Arm ) A minimum 10 center 7 ( Denmark , Sweden , Norway , UK , Belgium , The Netherlands Germany ) Study treatment : Patients randomize 1:1 receive either placebo Pirfenidone . Pirfenidone dose adapt per Investigator 's Brochure case adverse event Selection criterion : Inclusion criterion : Patients include irrespective pre-transplant disease , type induction treatment immunosuppressive treatment . The following patient include study : - Patients &gt; 18 year age - Azithromycin therapy least 4 week prior study start , Azithromycin dose minimum 250 mg/day least 3 time per week consider standard therapy bronchiolitis obliterans syndrome . - Double lung transplantation require . - Patients must least 6 month transplantation must document post-transplant baseline value FEV1 ( mean 2 high value measure least 3 week apart accord ISHLT criterion ) . - Patients must BOS grade 1 BOS grade 3 . - Patients must document progressive disease demonstrate follow criterion : - Patients must least 3 FEV1-measurements last 6 month , least 3 week apart - total decline least 200ml FEV1 last three measurement - decline least 50 ml last two measurement Exclusion Criteria : - Patients lung redo transplantation , combine transplantation ( include heart lung transplantation ) single lung recipient . - Patients severe comorbidity complicate BOS might determine prognosis functional level patient ( e.g . invasive aspergillosis , active malignant disease ) within last 12 month . - FEV1 decline relate non BOS cause ( eg pneumothorax , bronchial stenosis , effusion , etc . ) - Patients Thorax CT entry demonstrate new significant finding compatible BOS like interstitial fibrosis , consolidation , appearance suggest Restrictive Allograft Syndrome ( RAS ) acute pulmonary infection cause decline lung function . - Documented acute perivascular rejection high grade A1 finding compatible antibody mediate rejection - Pregnancy lactation ( woman childbearing capacity require negative serum pregnancy test treatment must agree maintain highly effective contraception practice abstinence use least two method birth control date consent end study ) . - Renal insufficiency ( Creatinine clearance &lt; 30 ml/min calculate CKD-Epi formula . - Any following liver test criterion specify limit : - Total bilirubin upper limit normal range ( ULN ) , except patient predominantly unconjugated hyperbilirubinemia ( e.g. , Gilbert 's syndrome ) - Aspartate alanine aminotransferase ( AST ALT ) &gt; 3 × ULN - Known allergy hypersensitivity Pirfenidone - Ongoing use expect use follow therapy : - Strong inhibitor CYP1A2 ( e.g . fluvoxamine enoxacin ) - Moderate inhibitor CYP1A2 ( e.g . mexiletine , thiabendazole , phenylpropanolamine [ Note : ciprofloxacin allow dos ≤500 mg BID ] ) - Previous treatment Pirfenidone transplantation - Patients resume smoke transplantation Data collection At screening : - Thorax HR-CT ( exclude non-BOS pathology ) - Chest X Ray - Spirometry measurement FEV1/FVC accord ERS criterion require demonstrate typical obstruction - ECG exclude QTc &gt; 500ms - Bronchoscopy bronchoalveolar lavage ( BAL ) accord standard international criterion . At least two aliquot 50 ml require . BAL exclude concurrent infection . BAL culture bacteria fungi plus cytospin preparation immunological BAL differential count . - Transbronchial biopsy - Blood sample ( haematology chemistry ) include liver function test - Drug monitor immuno-suppressive treatment Baseline : - Height - Weight - Basic demographic data include medication . - Physical examination vital sign - Spirometry measurement FEV1/FVC - Blood sample ( haematology chemistry ) include liver function test - Drug monitor immuno-suppressive treatment - Record concomitant medication - Body-plethysmographic measurement ass TLC RV - DLco - 6MWT - Quality Life questionnaire Monthly visit ( Months 1 , 2 , 3 , 4 ) : - Weight - Spirometry measurement FEV1/FVC accord ATS/ERS criterion . - Safety monitoring ( Record ADRs blood lab test , include liver test ) - Drug monitoring immuno-suppressive treatment - Record concomitant medication - Clinical Status Endpoints : 6 Month visit ( early termination visit ) : - Weight - Spirometry measurement FEV1/FVC accord ATS/ERS criterion . - Safety monitoring ( Record ADRs blood lab test , include liver test ) - Drug monitoring immuno-suppressive treatment - Record concomitant medication - Clinical Status - Body-plethysmographic measurement ass TLC RV - DLco - 6MWT - Quality Life questionnaire Primary endpoint - Change FEV1 ( ml ) 6 month Secondary endpoint - Categorical percentage change FEV1 ( ml ) Categorical percentage change FEV1 ≥ 10 % ( increase decrease ) relative FEV1 ( ml ) baseline - Change FVC liters - Change TLC liters - FEV1/FVC ratio change - Number patient treatment failure - Change BOS grade - Change percent predict DLco . - Change functional level assess 6MWT - Hospital admission reason - Death re-transplantation rate - Change EQ5D scale Treatment failure study define one following : - Redo transplantation - Death due respiratory cause - Initiation rescue therapy worsen BOS ( worsen BOS define decline least 600mL 3 consecutive month ) Photophoresis , Montelukast treatment consider rescue therapy investigator Statistical Methods Imputation : In ITT primary endpoint analysis , miss data due treatment failure death impute 50 % baseline FEV1 . For patient lose follow-up withdrew study reason related BOS , last measure FEV1 ( ml ) impute 6 month value . Sample Size calculation : Assumptions : 1 . SD : To determine SD FEV1 decline population , 5 member Steering committee collect data patient meet inclusion criterion . Mean decline FEV1 ( 6 month period ) sample 561 ml SD decline 300 ml . 2 . Treatment effect : A meaningful treatment effect 50 % expect base mechanism disease preliminary data BOS ( In publication ) personal experience . One standard deviation ( SD ) FEV1 group assume 300 mL base data expert center . Monthly decline FEV1 onset BOS assume approximately 75 ml , 6 month 450 ml decline FEV1 expect placebo group . A treatment effect 50 % reduction decline expect Pirfenidone , lead expect mean decline 225 ml 6 month . With beta error 12 % ( power 88 % ) study able detect difference 225 ml two treatment group sample size 36 patient group use two-sided t-test significance level 0.05 . An estimated 80 patient recruit trial allow drop-out rate 10 % . Concomitant treatment - Stopping Azithromycin allow tolerate . Standard treatment continuation Azithromycin . - Initiation new bronchodilator therapy allow - Photopheresis Montelukast allow Pirfenidone Study Committees Steering Committee : M. Perch , P. Corris , G. Verleden , J. Gotlieb E Verschuuren Patient Review Committee Inclusion Criteria , exclusion criterion BOS stag patient enrol reviewed committee . Clinical Events Committee Group physicians review serious adverse event occur study adjudicate relationship study drug . DSMB Independent group review safety efficacy data study .</detailed_description>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Patients &gt; 18 year age Azithromycin therapy least 4 week prior study start , Azithromycin dose minimum 250 mg/day least 3 time per week consider standard therapy bronchiolitis obliterans syndrome . Double lung transplantation require . Patients must least 6 month transplantation must document posttransplant baseline value FEV1 ( mean 2 high value measure least 3 week apart accord ISHLT criterion ) . Patients must BOS grade 1 BOS grade 3 . Patients must document progressive disease demonstrate follow criterion : Patients must least 3 FEV1measurements last 6 month , least 3 week apart total decline least 200ml FEV1 decline least 50 ml last two measurement Exclusion Criteria Patients lung redo transplantation , combine transplantation ( include heart lung transplantation ) single lung recipient . Patients severe comorbidity complicate BOS might determine prognosis functional level patient ( e.g . invasive aspergillosis , active malignant disease ) within last 12 month . FEV1 decline relate non BOS cause ( eg pneumothorax , bronchial stenosis , effusion , etc . ) Patients develop BOS grade 3 . Patients Thorax CT entry demonstrate new significant finding compatible BOS like interstitial fibrosis , consolidation , appearance suggest Restrictive Allograft Syndrome ( RAS ) acute pulmonary infection cause decline lung function . Documented acute perivascular rejection high grade A1 finding compatible antibody mediate rejection Pregnancy lactation ( woman childbearing capacity require negative serum pregnancy test treatment must agree maintain highly effective contraception practice abstinence use least two method birth control date consent end study ) . Renal insufficiency ( Creatinine clearance &lt; 30 ml/min calculate CKDEpi formula . Any following liver test criterion specify limit : Total bilirubin upper limit normal range ( ULN ) , except patient predominantly unconjugated hyperbilirubinemia ( e.g. , Gilbert 's syndrome ) Aspartate alanine aminotransferase ( AST ALT ) &gt; 3 × ULN Known allergy hypersensitivity Pirfenidone Ongoing use expect use follow therapy : Strong inhibitor CYP1A2 ( e.g . fluvoxamine enoxacin ) Moderate inhibitor CYP1A2 ( e.g . mexiletine , thiabendazole , phenylpropanolamine [ Note : ciprofloxacin allow dos ≤500 mg BID ] ) Previous treatment Pirfenidone transplantation Patients resume smoke transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>